10,077 Shares in Prestige Consumer Healthcare Inc. $PBH Acquired by Van Hulzen Asset Management LLC

Van Hulzen Asset Management LLC purchased a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the 2nd quarter, Holdings Channel.com reports. The institutional investor purchased 10,077 shares of the company’s stock, valued at approximately $476,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PBH. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 110.1% during the 4th quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after buying an additional 219 shares during the period. Barrow Hanley Mewhinney & Strauss LLC bought a new stake in shares of Prestige Consumer Healthcare in the second quarter valued at about $30,000. Versant Capital Management Inc grew its stake in shares of Prestige Consumer Healthcare by 47.9% in the second quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after acquiring an additional 235 shares in the last quarter. Torren Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at about $35,000. Finally, Caitong International Asset Management Co. Ltd increased its position in Prestige Consumer Healthcare by 69.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock worth $35,000 after acquiring an additional 236 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on PBH. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Canaccord Genuity Group decreased their target price on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, August 10th. Finally, Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Two investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $70.75.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH opened at $51.38 on Wednesday. The company’s 50 day simple moving average is $49.90 and its 200 day simple moving average is $54.84. The stock has a market capitalization of $2.43 billion, a price-to-earnings ratio of 14.39, a price-to-earnings-growth ratio of 1.63 and a beta of 0.34. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. Prestige Consumer Healthcare Inc. has a 1 year low of $42.62 and a 1 year high of $71.07.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. During the same period in the prior year, the company earned $0.90 earnings per share. The company’s quarterly revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, research analysts predict that Prestige Consumer Healthcare Inc. will post 4.56 EPS for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).